This Compendium represents what we believe to be the most current and reliable pharmacological data on anticonvulsant drugs. The information presented is derived from determinations of the drugs in plasma or serum by gas-liquid chromatography in studies of the efficacy of anti-epileptic agents. We present information on the limitations of therapeutic concentration ranges, half-lives, active and inactive metabolites, and structure/activity relationships of anticonvulsant drugs. This report provides answers to many of the questions clinicians direct to anticonvulsant-monitoring laboratories. Information on other pharmacological variables supplements this review in the interest of the clinical investigator.
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The evidence that anticonvulsants exert their therapeutic effects at biological sites in the brain still remains empirical. The plasma is a readily obtainable body fluid for use in the practical measurement of anticonvulsant concentrations at their active site(s). Since almost all of the anticonvulsant drugs listed here accumulate as parent or metabolite during chronic administration, the stable concentrations in plasma should be in equilibrium with the drug at its active site(s).
With the advent of gas-liquid chromatography in clinical studies of this group of drugs, a positive relationship between the concentrations of several anticonvulsants in the plasma and their efficacy in seizure control has been demonstrated.
Consequently We frequently receive calls in our laboratory in the Epilepsy Center from clinicians and clinical investigators requesting specific pharmacological data, the concentrations to be expected or sought in plasma, metabolites, etc., for this particular drug group. Several researchers in clinical and laboratory settings have presented reliable and reproducible data in independent assessments analyzing the efficacy of anti-epileptic medication and correlations with concentrations in plasma. Various reviews (2) (3) (4) of these clinical and pharmacological investigations have contributed information for this compendium.
Gaps or omissions in the tables signify either unavailable data or results that are questionable or supported by too few observations. Select information on the more obscure drugs is presented in the interest of clinical investigators.
The information in Table 1 on ranges for therapeutic concentrations of drugs in plasma is derived primarily from analysis by gas-liquid chromatography.
The use of therapeutic ranges has been extensively discussed (5), especially when physicians place more emphasis on the analytical values than on an individual patient's clinical status. Such ranges are no guarantee of seizure control but merely provide the best estimate as to an optimal range for a heterogeneous seizure population. Because seizures represent a graded phenomenon, individual variations will exist, and patients with high drug concentrations in their plasma may continue to have seizures while others improve with concentrations that are below what is currently considered to be the therapeutic range.
Drugs and their metabolites listed under the "Therapeutic plasma concentration range" heading of Table The biological half-life data in Table 1 was accumulated from studies in epileptic patients on chronic, single-drug regimens. Drug interactions during combination therapy that result in deviations from the stated half-lives and concentrations in serum have been documented (6) but are too numerous and complex to include in these tables. Differences existing between half-lives after single vs. chronic dosing have been documented with carbamazepine (7), but remain speculative for others. Common to almost all of the anticonvulsants listed here is their long biological half-life. This makes it possible to attain stable concentrations in plasma in chronic dosing and contributes to the effectiveness of these drugs in seizure control. Table 2 summarizes the metabolites derived from the major anti-epileptic drugs in human volunteers or patients. Although many of the metabolites have no anticonvulsant effect, measurement of some has been useful in assessing reliability of drug intake, completeness of absorption, or abnormalities in metabolism, as with p -hydroxydiphenylhydantoin, a metabolite of phenytoin that appears in the urine.
The similarity of the heterocyclic ring structure in most of the anti-epileptic drugs is apparent in Figure  1 . In attempts to correlate chemical structure with anticonvulsant selectivity, it appears that aromatic sub- 
